Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating Expenses:
Research and development	$ 3,278	$ 5,076
General and administrative	3,342	3,010
Total operating expenses	6,620	8,086
Operating loss	(6,620)	(8,086)
Other income (expense):
Investment income, net	63	23
Other expense, net	(148)	0
Total other (expense) income	(85)	23
Net loss before benefit from income taxes and noncontrolling interests	(6,705)	(8,063)
Benefit from income taxes	(2,479)	0
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,226)	$ (8,063)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)	$ (0.07)	$ (0.19)
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)	$ (0.07)	$ (0.19)
Weighted average common shares outstanding
Basic shares	60,560	42,117
Diluted shares	60,560	42,117